John Gunn - Dodge & Cox
Holding/activity history for Alnylam Pharmaceuticals (ALNY)
| Period | Shares | % of Portfolio | Activity | % Change to Portfolio | Reported Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026 Q1 | 1,929,253 | 0.35 | Reduce 1.79% | <0.01 | $330.87 | $638,331,940 | SEC |
| 2025 Q4 | 1,964,415 | 0.42 | Reduce 15.37% | 0.09 | $397.65 | $781,149,625 | SEC |
| 2025 Q3 | 2,321,230 | 0.57 | Reduce 27.40% | 0.16 | $456.00 | $1,058,480,880 | SEC |
| 2025 Q2 | 3,197,096 | 0.59 | Reduce 4.61% | 0.02 | $326.09 | $1,042,541,035 | SEC |
| 2025 Q1 | 3,351,762 | 0.52 | Reduce 5.32% | 0.03 | $270.02 | $905,042,775 | SEC |
| 2024 Q4 | 3,540,262 | 0.48 | Reduce 2.27% | 0.01 | $235.31 | $833,059,051 | SEC |
| 2024 Q3 | 3,622,535 | 0.56 | Reduce 4.17% | 0.02 | $275.03 | $996,305,801 | SEC |
| 2024 Q2 | 3,780,185 | 0.55 | Reduce 0.82% | <0.01 | $243.00 | $918,584,955 | SEC |
| 2024 Q1 | 3,811,480 | 0.33 | Add 3.73% | 0.01 | $149.45 | $569,625,686 | SEC |
| 2023 Q4 | 3,674,310 | 0.45 | Reduce 1.94% | <0.01 | $191.41 | $703,299,677 | SEC |
| 2023 Q3 | 3,747,155 | 0.45 | Reduce 1.12% | <0.01 | $177.10 | $663,621,151 | SEC |
| 2023 Q2 | 3,789,525 | 0.48 | Reduce 2.70% | 0.01 | $189.94 | $719,782,379 | SEC |
| 2023 Q1 | 3,894,535 | 0.53 | Reduce 15.17% | 0.11 | $200.32 | $780,153,251 | SEC |
| 2022 Q4 | 4,590,782 | 0.75 | Reduce 6.11% | 0.05 | $237.65 | $1,090,999,342 | SEC |
| 2022 Q3 | 4,889,297 | 0.74 | Reduce 7.03% | 0.04 | $200.16 | $978,642,000 | SEC |
| 2022 Q2 | 5,258,956 | 0.53 | Reduce 3.96% | 0.02 | $145.85 | $767,019,000 | SEC |
| 2022 Q1 | 5,475,668 | 0.55 | Add 0.82% | <0.01 | $163.29 | $894,122,000 | SEC |
| 2021 Q4 | 5,431,068 | 0.57 | Add 1.10% | <0.01 | $169.58 | $921,001,000 | SEC |
| 2021 Q3 | 5,372,100 | 0.66 | Reduce 0.77% | <0.01 | $188.81 | $1,014,306,000 | SEC |
| 2021 Q2 | 5,414,001 | 0.60 | Add 25.28% | 0.12 | $169.52 | $917,781,000 | SEC |
| 2021 Q1 | 4,321,627 | 0.44 | Reduce 6.86% | 0.03 | $141.19 | $610,171,000 | SEC |
| 2020 Q4 | 4,639,913 | 0.48 | Reduce 0.81% | <0.01 | $129.97 | $603,049,000 | SEC |
| 2020 Q3 | 4,677,613 | 0.62 | Reduce 0.55% | <0.01 | $145.60 | $681,060,000 | SEC |
| 2020 Q2 | 4,703,671 | 0.64 | Reduce 7.65% | 0.05 | $148.11 | $696,661,000 | SEC |
| 2020 Q1 | 5,093,346 | 0.60 | Reduce 3.01% | 0.01 | $108.85 | $554,411,000 | SEC |
| 2019 Q4 | 5,251,321 | 0.46 | Reduce 1.14% | <0.01 | $115.17 | $604,795,000 | SEC |
| 2019 Q3 | 5,311,801 | 0.35 | Add 1.34% | <0.01 | $80.42 | $427,175,000 | SEC |
| 2019 Q2 | 5,241,501 | 0.31 | Add 4.87% | 0.01 | $72.56 | $380,323,000 | SEC |
| 2019 Q1 | 4,998,001 | 0.39 | Add 6.56% | 0.02 | $93.45 | $467,063,000 | SEC |
| 2018 Q4 | 4,690,251 | 0.31 | Add 0.74% | <0.01 | $72.91 | $341,966,000 | SEC |
| 2018 Q3 | 4,655,651 | 0.31 | Add 0.02% | <0.01 | $87.52 | $407,463,000 | SEC |
| 2018 Q2 | 4,654,701 | 0.37 | Reduce 0.81% | <0.01 | $98.49 | $458,442,000 | SEC |
| 2018 Q1 | 4,692,841 | 0.46 | Reduce 42.99% | 0.36 | $119.10 | $558,917,000 | SEC |
| 2017 Q4 | 8,231,595 | 0.83 | Reduce 9.95% | 0.09 | $127.05 | $1,045,824,000 | SEC |
| 2017 Q3 | 9,141,495 | 0.89 | Reduce 0.48% | <0.01 | $117.49 | $1,074,034,000 | SEC |
| 2017 Q2 | 9,185,820 | 0.63 | Reduce 2.27% | <0.01 | $79.76 | $732,661,000 | SEC |
| 2017 Q1 | 9,399,245 | 0.42 | Add 2.11% | <0.01 | $51.25 | $481,711,000 | SEC |
| 2016 Q4 | 9,204,950 | 0.31 | Add 74.47% | 0.13 | $37.44 | $344,633,000 | SEC |
| 2016 Q3 | 5,276,068 | 0.34 | Add 109.64% | 0.18 | $67.78 | $357,612,000 | SEC |
| 2016 Q2 | 2,516,669 | 0.14 | Buy | 0.14 | $55.49 | $139,650,000 | SEC |